Novartis pay-for-silence retreat is first of many
Finding the limit
In the face of public fury, the Swiss drugmaker has cancelled $78 mln in non-compete payments to its retiring chairman. Daniel Vasella’s case was extreme: ultra-high reward for essentially no action in an egalitarian land. But it sets a strong precedent for activists everywhere.
This content is for Subscribers only
To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.